Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5691671 | 0.89 | GPR119 (0.39) | GRIN2BCYP2D6CYP2C9CYP3A4LIPE | |
| SCHEMBL5689023 | 0.88 | GRIN2B (0.41) | GRIN2BLIPEMGLL | |
| SCHEMBL5691280 | 0.87 | ALDH1A1 (0.36) | GRIN2BCYP2D6CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL5691062 | 0.87 | FAAH (0.40) | CYP2D6CYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL5687850 | 0.85 | GRIN2B (0.39) | GRIN2BCYP2D6CYP2C9CYP3A4CYP1A2 | |
| SCHEMBL5687670 | 0.82 | TBXAS1 (0.42) | GRIN2BCYP2C9CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL5688663 | 0.82 | SLC2A1 (0.42) | GRIN2BMGLLTHRBLTA4H | |
| SCHEMBL5689147 | 0.82 | HSD11B1 (0.42) | GRIN2BCYP2D6CYP2C9CYP3A4LIPE | |
| SCHEMBL5688946 | 0.81 | GRIN2B (0.39) | GRIN2BLIPEMGLL | |
| SCHEMBL5691503 | 0.81 | GRIN2B (0.41) | GRIN2BLIPETBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636207-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111032-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1636207-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111032-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | LIPE, PNLIP, LIPC | GRIN2B 2588/4885CYP2D6 3231/4885CYP2C9 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.